<ul> <li>Adding a new CAR co-stimulatory domain (TLR2) to a conventional CD28-costimulated anti-CD19 CAR T-cell reduces cytokine release syndrome- and neurotoxicity-associated cytokines.</li> <li>25 patients with relapsed or refractory B-cell non-Hodgkin lymphomas received CD28/TLR2 co-stimulated anti-CD19 CAR T-cells in a phase 1 dose escalation and expansion trial.</li> <li>No severe CRS and no ICANS neurotoxicity of any grade occurred. Complete responses were seen at doses from 5 × 10<sup>4</sup> to 1 × 10<sup>6</sup> cells/kg.</li> <li>Outpatient therapy and automated manufacture have been established in preparation for a phase 2 trial.</li>
</ul>